Gestational diabetes & diabetes in pregnancy
Efficacy and safety of pharmacological treatments for gestational diabetes: a systematic review comparing metformin with glibenclamide and insulin
Authors' conclusion
Metformin (Glucophage) appears to be a promising alternative to insulin for treating gestational diabetes, while uncertainties remain regarding the safety of glibenclamide.
Study context
- Population
- Women with GDM; PubMed and Google Scholar, 2013–202345 studies
- Comparison
- Metformin vs glibenclamide and insulin
- Outcome
- Effectiveness and safety of treatments in GDM
Pooled result
As reported in the abstract
- Metformin appears to combine effective glycaemic control with maternal and neonatal safety
- Metformin vs insulin: less maternal weight gain, lower maternal hypoglycaemia rates, tendency to less gestational hypertension and preeclampsia
- Infants of mothers on metformin: less macrosomia, fewer neonatal hypoglycaemic episodes, fewer ICU admissions
- Glibenclamide seems effective in glycaemic control
Safety
- Glibenclamide associated with higher rates of macrosomia and neonatal hypoglycaemia
Original publication
Efficacy and safety of pharmacological treatments for gestational diabetes: a systematic review comparing metformin with glibenclamide and insulin. Diabetes Metab. Published 7 February 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →